Advertisement
Advertisement
RCKT
Rocket Pharmaceuticals, Inc. Common Stock
3.41
USDSponsored
+0.30
+9.65%
Aug 03, 15:54 UTC -4
Closed
After-Market
3.40
-0.01
-0.15%
RCKT Earnings Reports
Positive Surprise Ratio
RCKT beat 25 of 40 last estimates.
63%
Next Report
Next Week
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$20.40M
/$0.38
Implied change from Q1 26 (Revenue/ EPS)
--
/-190.48%
Implied change from Q2 25 (Revenue/ EPS)
--
/-164.41%
Rocket Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On May 07, 2026, RCKT reported earnings of -0.42 USD per share (EPS) for Q1 26, missing the estimate of -0.41 USD, resulting in a -1.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.09% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 10 analysts forecast an EPS of 0.38 USD, with revenue projected to reach 20.40 million USD, implying an decrease of -190.48% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Bicycle Therapeutics plc - ADR
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$0.58
Actual
-$0.72
Surprise
-22.64%
Compugen Ltd
Report Date
Aug 03, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.07
Surprise
+14.22%
Vertex Pharmaceuticals Inc
Report Date
Aug 03, 2026 For Q2 26
Estimate
$4.82
Actual
$4.73
Surprise
-1.95%
Moderna, Inc. Common Stock
Report Date
Jul 31, 2026 For Q2 26
Estimate
-$2.12
Actual
-$1.97
Surprise
+7.28%
Illumina Inc
Report Date
Jul 30, 2026 For Q1 26
Estimate
$1.25
Actual
$1.31
Surprise
+4.74%
Illumina Inc
Report Date
Jul 30, 2026 For Q2 26
Estimate
$1.38
Actual
$1.31
Surprise
-5.30%
Krystal Biotech, Inc. Common Stock
Report Date
Aug 03, 2026 For Q2 26
Estimate
$1.68
Actual
$1.79
Surprise
+6.00%
TG Therapeutics, Inc.
Report Date
Aug 03, 2026 For Q2 26
Estimate
$0.33
Actual
$0.05
Surprise
-84.97%
Twist Bioscience Corporation Common Stock
Report Date
Aug 03, 2026 For Q3 26
Estimate
-$0.50
Actual
-$0.56
Surprise
-11.20%
Disc Medicine, Inc. Common Stock
Report Date
Jul 30, 2026 For Q2 26
Estimate
-$1.78
Actual
-$1.54
Surprise
+13.63%
FAQ
What were Rocket Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Rocket Pharmaceuticals, Inc. Common Stock reported EPS of -$0.42, missing estimates by -1.18%, and revenue of $0.00, 0% as expectations.
How did the market react to Rocket Pharmaceuticals, Inc. Common Stock's Q1 2026 earnings?
The stock price moved down -1.09%, changed from $3.67 before the earnings release to $3.63 the day after.
When is Rocket Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Rocket Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 10
analysts, Rocket Pharmaceuticals, Inc. Common Stock is expected to report EPS of $0.38 and revenue of $20.40M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement